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Abstract
Background: To investigate the significance of Aurora B expression in hepatocellular carcinoma (HCC).
Methods: The Aurora B and Aurora A mRNA level was measured in 160 HCCs and the paired nontumorous liver
tissues by reverse transcription-polymerase chain reaction. Mutations of the p53 and b-catenin genes were analyzed
in 134 and 150 tumors, respectively, by direct sequencing of exon 2 to exon 11 of p53 and exon 3 of b-catenin.
Anticancer effects of AZD1152-HQPA, an Aurora B kinase selective inhibitor, were examined in Huh-7 and Hep3B
cell lines.
Results: Aurora B was overexpressed in 98 (61%) of 160 HCCs and in all 7 HCC cell lines examined. The
overexpression of Aurora B was associated with Aurora A overexpression (P = 0.0003) and p53 mutation (P = 0.002)
and was inversely associated with b-catenin mutation (P = 0.002). Aurora B overexpression correlated with worse
clinicopathologic characteristics. Multivariate analysis confirmed that Aurora B overexpression was an independent
poor prognostic factor, despite its interaction with Aurora A overexpression and mutations of p53 and b-catenin.I n
Huh-7 and Hep3B cells, AZD1152-HQPA induced proliferation blockade, histone H3 (Ser10) dephosphorylation, cell
cycle disturbance, and apoptosis.
Conclusion: Aurora B overexpression is an independent molecular marker predicting tumor invasiveness and poor
prognosis of HCC. Aurora B kinase selective inhibitors are potential therapeutic agents for HCC treatment.
Backgroud
Hepatocellular carcinoma (HCC) is the leading cause of
cancer mortality in Taiwan [1] and many other coun-
tries in Asia and Africa [2]. The incidence of HCC is
increasing in Europe and the United States [3]. In 2002,
HCC became the sixth most common cancer worldwide
with 626,000 annual new cases [4]. Despite surgical
resection, which provides an opportunity for cure, the
majority of patients with HCC have a dismal prognosis
[5] because tumor recurrence frequently develops and
usually leads to patient’s mortality [6]. The development
of HCC is closely related to chronic hepatitis B or C,
cirrhosis of any etiology, and aflatoxin B1 exposure [2].
However, the detailed molecular mechanisms of hepato-
carcinogenesis are still not fully understood [7]; molecu-
lar factors capable of predicting clinical outcome of
HCC and acting as potential therapeutic targets remain
limited. The identification of molecular markers related
to hepatocarcinogenesis, tumor progression, and poor
clinical outcome would benefit patients, providing for
better management planning and serving as potential
therapeutic targets for novel HCC drug treatments.
Genomic instability has been correlated with hepato-
carcinogenesis [8], and increased chromosomal instabil-
ity has been associated with differentiation status of
human HCC [9]. Aurora kinases, a subfamily of serine/
threonine mitotic kinases, are thought to be key mole-
cules required for maintaining accurate cell cycling and
genomic stability [10]. We previously showed that
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HCCs and that the overexpression of Aurora A was
associated with aggressive tumor characteristics and
poor prognosis of patients [11]. Furthermore, we
demonstrated that VE-465, a novel pan-Aurora kinase
inhibitor, had anticancer effects in preclinical models of
human HCC [12]. These findings indicated that Aurora
kinases may be important biomarkers and potential
therapeutic targets in HCC.
There are three highly related Aurora kinases in mam-
mals, Aurora A, B, and C. Aurora A and Aurora B share
ah i g hd e g r e eo fs e q u e n c eh o m o l o g yi nt h e i rc a t a l y t i c
domains, and overexpression of each has been identified
in many human cancers [13].
Despite their sequence similarity, Aurora A and Aur-
ora B differ in chromosomal gene loci, subcellular locali-
zation, cellular functions, and signaling substrates [13].
The Aurora A kinase gene is localized to chromosome
20q13.2, and that for Aurora B kinase is localized to
chromosome 17p13.1. Aurora A kinase protein is loca-
lized in the centrosome and spindle poles and plays
important roles in centrosome maturation and spindle
assembly [14]. Aurora B kinase, which is a chromosome
passenger protein localized in the centromeres during
early mitosis and then at the spindle midzone after ana-
phase, is essential for chromosome biorientation, func-
tion of the spindle assembly checkpoint, and cytokinesis
[15]. The enthusiasm of exploring Aurora kinases as
anticancer therapeutic targets initially centered on Aur-
ora A, but recent studies have demonstrated that several
Aurora kinase inhibitors exhibit anticancer activity
resembling that of Aurora B disruption induced by
genetic methods [16]. Therefore, determination of the
distinctive roles in carcinogenesis and individual clinical
significance of Aurora A and Aurora B is mandatory.
The aims of this study were to elucidate the clinico-
pathologic significance of Aurora B expression and Aur-
ora A expression in HCC and to correlate their
expression with p53 and b-catenin mutations, the two
most frequently mutated genes in HCC [7,11].
Methods
Tissue samples
During the period January 1987 through December
1997, 160 surgically resected, primary unifocal HCCs
were selected for this study. After resection, tumor tis-
sues were immediately cut into small pieces, snap frozen
in liquid nitrogen, and stored in deep freezer. Patients
had received comprehensive pathologic assessment and
regular follow-up at National Taiwan University Hospi-
tal, as described previously [17,18]. This study was com-
pliant with the regulations of the Ethics Committee of
the host institution. The 160 patients included 122 men
and 38 women with a mean age of 57 years (range,
14-88 years). Serum hepatitis B surface antigen (HBsAg)
was detected in 107 cases (67%) and antihepatitis C
virus antibody in 53 (35%), including 13 positive for
both. Elevated a-fetoprotein (AFP; ≥200 ng/mL) was
detected in 80 cases (50%). Liver cirrhosis was found in
61 patients (38%). All patients had adequate liver func-
tion reserve at the time of surgery. None of the patients
had received local or systemic therapy before surgery.
Histological study and tumor staging
Tumor grade was divided into 3 groups: well-differen-
tiated (grade I, 31 cases), moderately differentiated
(grade II, 74 cases), and poorly differentiated (grade III-
IV, 55 cases). The unifocal HCC was staged as stages I,
II, IIIA, IIIB, and IV, as described previously [11,19,20].
Staging was based on the International Union Against
Cancer criteria, with slight modification because HCC
tends to spread in the liver via vascular invasion, which
is an important unfavorable prognostic factor for this
disease [21]. Stage I HCC included tumors that were ≤
2 cm and showed no evidence of liver and vascular inva-
sion (4 cases). Stage II HCCs included tumors that were
≤ 2 cm for which vascular invasion was limited to small
vessels in the tumor capsule, as well as encapsulated
tumors > 2 cm with no evidence of liver or vascular
invasion (62 cases). Stage IIIA HCCs included invasive
tumors > 2 cm with invasion of small vessels in the
tumor capsule and/or satellites near the tumor, but no
portal vein invasion (25 cases). Stage IIIB HCCs
included tumors with invasion of the portal vein branch
near the tumor, but not of the distant portal vein in the
liver parenchyma (23 cases). Stage IV included tumors
with involvement of major portal vein branches, satel-
lites extending deeply into the surrounding liver, tumor
rupture, or invasion of the surrounding organs (46
cases). No evidence of regional lymph node or distant
metastasis was noted at the time of surgery in any of
the cases. Among the 160 patients studied, 149 were eli-
gible for the evaluation of early tumor recurrence (ETR;
≤12 months). Eleven patients who died within 1 year
after surgery without objective evidence of tumor recur-
rence were excluded from the evaluation of ETR.
Reverse transcription-polymerase chain reaction
Reverse transcription-polymerase chain reaction (RT-
PCR) was used to determine the mRNA levels of Aurora
A and Aurora B in paired HCCs and nontumorous liver
samples, as described elsewhere [11,22]. The ribosomal
protein S26 mRNA, a housekeeping gene, was used as
an internal control [23]. Briefly, total RNA was isolated
from the frozen tissues using a guanidium isothiocya-
nate/CsCl method. RNA was quantified by spectropho-
tometry at 260 nm. Stock RNA samples were kept in
alcohol in deep freezer until used. Complementary DNA
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HCCs and nontumorous liver samples. Two microliter
reverse transcription product, 1.25 units Pro Taq poly-
merase (Protech Technology Enterprise, Taipei, Taiwan),
Pro Taq buffer, and 200 μMd A T P ,d C T P ,d G T P ,a n d
dTTP (each) were mixed with primer pairs for Aurora
A, Aurora B,a n dS26 in a total volume of 30 μl. One-
tube PCR reaction was stopped at the exponential phase
of gene amplification: 29 cycles for Aurora A,3 2f o r
Aurora B, and 23 for S26. The reaction was performed
in an automatic DNA thermal cycler (model 480; Per-
kin-Elmer Co., Wellesley, MA), with limited reaction
reagents (Tag enzyme and dNTPs), and processed with
initial heating at 94°C for 2 minutes, followed by 29
(Aurora A)o r3 2( Aurora B) PCR reaction cycles of 94°
C for 30 seconds, annealing at 60°C for 1 minute, exten-
sion at 72°C for 1 minute, and a final 72°C extension for
10 minutes. The PCR reaction was stopped at cycle 7
(Aurora A)o r1 0( Aurora B), and the reaction tubes
were quenched on ice to allow adding S26 primers, then
complete the final 23 PCR reaction cycles. Primers for
amplified genes were as follows: Aurora A-F (AATTG
CAGATTTTGGGTGGT), Aurora A-R (AAACTTCAG
TAGCATGTTCCTGTC), Aurora B-F (ATCGTGG
CGCTCAAGGTCCT), Aurora B-R (GATGCACTCT
CAAAGGGTGGG), S26-F (CCGTGCCTCCAAGAT-
GACAAAG), S26-R (GTTCGGTCCTTGCGGGCTTC
AC). The PCR products were electrophoresed on a 2%
agarose gel. Concentrations of the PCR fragments were
determined with the IS-1000 digital imaging system
(Alpha Innotech, San Leandro, CA). The Aurora A and
Aurora B mRNA levels were determined according to
the ratio of signal intensity for Aurora A or B to that of
S26 as measured by 1 D Image Analysis software
(Kodak Digital Science, Rochester, NY) and scored as
high (ratio >1.0), moderate (ratio > 0.5 and ≤1.0), or low
(ratio ≤0.5). The Aurora A and Aurora B mRNA levels
of nontumorous liver rarely exceeded a ratio of 0.5, and
a ratio > 0.5 was regarded as overexpression.
Analysis of p53 and b-catenin mutations
Mutations of the p53 and b-catenin genes were analyzed
in 134 and 150 tumors, respectively, by direct sequen-
cing of exon 2 to exon 11 of p53 and exon 3 of b-cate-
nin, as described previously [17,24,25]. Samples with
incomplete study results were excluded from statistical
analysis.
Follow-up observation and assessment of early tumor
recurrence
Early tumor recurrence (ETR) was designated as intra-
hepatic tumor recurrence or distant metastasis detected
by imaging tools, pathology and/or high AFP levels
within 12 months. All 160 patients had been followed
for more than 5 years or until death. At the end of the
follow-up in November 2008, 37 patients remained
alive. One hundred forty-nine cases (93%) were eligible
for evaluation of ETR.
Seventy-three (46%) cases had ETR. Among the 73
patients, 11 (15%), 26 (36%), 7 (10%), 1 (1%) received
tumor resection, transhepatic arterial embolization, che-
motherapy, or radiotherapy, respectively. Fifty-one (32%)
of the 160 cases had late tumor recurrence more than
12 months after the initial hepatectomy. Among the 51
p a t i e n t s ,1 8( 3 5 % ) ,2 4( 4 7 % ) ,4( 8 % ) ,2( 4 % )r e c e i v e d
tumor resection, transhepatic arterial embolization, che-
motherapy, or radiotherapy, respectively.
Cell culture and reagents
The liver cancer cell lines Huh-7, HepG2, Hep3B, PLC5,
HCC36, HA59T, SK-hep-1, and Tong were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) plus 10%
fetal bovine serum (FBS), supplemented with penicillin
and streptomycin. Cells were maintained in a humidified
incubator with 5% CO2 in air at 37°C.
AZD1152-HQPA is a selective inhibitor of Aurora B
(inhibition constant Ki, 0.36 nM) compared with Aurora
A (inhibition constant Ki, 1369 nM) [26]. AZD1152-
HQPA, provided by AstraZeneca Pharmaceuticals (Mac-
clesfield, UK), was used for in vitro cell line studies.
Western blot analysis
Western blotting was performed as described previously
[11]. The following primary antibodies were used: anti-
Aurora B (Novus Biologicals, Littleton, CO, USA), anti-
Aurora A (Novus Biologicals), anti-a-tubulin antibody
(Sigma-Aldrich, St. Louis, MO, USA), anti-phosphory-
lated histone H3 (Ser10) (Santa Cruz Biotechnology,
I n c . ,S a n t aC r u z ,C A ,U S A ) ,a n da n t i - p h o s p h o r y l a t e d
Aurora A (T288) (Cell Signaling Technology, Inc., Dan-
vers, MA, USA). The final images were developed with
a chemiluminescence reagent.
Cell viability and flow cytometry
A total of 5 × 10
4 Huh-7 or Hep3B cells were plated in
six-well plates. After overnight culture, cells were trea-
ted with DMSO or 1, 5, 25, and 125 nM of AZD1152-
HQPA. At 72 hours of drug treatment, cells were trypsi-
nized and the total number of cells were counted using
hemocytometer. Trypan blue dye exclusion assay was
used to determine the number of viable cells. The
experiments were carried out in 3-4 replicates and
repeated trice.
Cells in logarithmical growth were incubated with
either AZD1152-HQPA or DMSO for 24 to 48 hours.
Cells were labeled with 0.5~1 mL propidium iodide (50
μg/mL) after being trypsinized and fixed in 70% metha-
nol overnight. Cell cycle profiles and sub-G1 fractions
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son, San Jose, CA, USA).
Statistical analysis
Data analyses were carried out with Statistical Analysis
System software (version 9.1; SAS Institute, Inc., Cary,
NC). Two-tailed P < 0.05 was considered statistically
significant. The c
2,F i s h e r ’s exact test, and log-rank test
were used for univariate analyses. Multivariate analyses
were conducted for ETR, tumor size, stage, and grade
by fitting multiple logistic regression models [27]. Time
to death was analyzed by fitting multiple Cox’sp r o p o r -
tional hazards models [28]. In our regression analyses,
basic model-fitting techniques for (a) variable selection,
(b) goodness-of-fit assessment, and (c) regression diag-
nostics (including residual analysis, influence analysis,
and check of multicollinearity) were used to ensure the
quality of the analysis results [27,28].
For the in vitro studies, the mean differences among
groups were tested by one-way analysis of variance
(ANOVA) followed by multiple comparisons using the
Dunnett’s post hoc test or the Bonferroni’s correction of
alpha level.
Results
Expression of Aurora B mRNA and protein in liver and
hepatocellular carcinoma
Using RT-PCR in the linear range, Aurora B mRNA
overexpression was detected in 98 (61%) of 160 surgi-
cally resceted, primary unifocal HCC specimens (Fig.
1A). Of these 160 HCCs, RNA samples of nontumorous
liver were examined in 153 cases. In nontumorous liver,
overexpression of Aurora B mRNA at a moderate level
was detected in 2 cases (1.3%). We then examined Aur-
ora B gene expression in cell lines, and all 7 liver cancer
cell lines showed high expression levels of Aurora B
mRNA, which correlated with protein levels (Fig. 1B).
Clinicopathologic significance of Aurora B mRNA
overexpression in hepatocellular carcinoma
To elucidate the biologic significance of Aurora B in
HCC, we correlated Aurora B expression with major
clinicopathologic features of HCC. As shown in Table 1,
Aurora B overexpression was associated with high
serum AFP level (≥200 ng/mL; P < 0.0001), but not with
age, gender, chronic hepatitis B/C virus infection, or
liver functional reserve (Child-Pugh class).
Histologically, Aurora B overexpression did not correlate
with the presence of liver cirrhosis. Nevertheless, HCCs
with Aurora B overexpression were associated with large
tumor size (> 5 cm; P = 0.021), high-grade histology (P =
0.0007), and advanced tumor stage (P < 0.0001).
Genes for p53, b-catenin,a n dAurora A are most fre-
quently deregulated in HCC and are closely associated
with HCC progression [7,11]. Therefore, relations
between Aurora B overexpression with mutations of p53
and b-catenin and with Aurora A overexpression were
analyzed. Table 1 shows that Aurora B overexpression
was correlated with Aurora A overexpression (P =
0.0003) and p53 mutation (P = 0.002). In contrast, Aur-
ora B was more frequently overexpressed in HCCs with-
out b-catenin mutation (P = 0.002).
Aurora B overexpression predicts early tumor recurrence
and poor prognosis
HCC with Aurora B overexpression were associated
with worse 5-year survival than HCC without Aurora B
overexpression (P < 0.0001; Table 1 and Fig. 2A). More-
over, HCC with Aurora B overexpression showed more
frequent ETR (P < 0.0001; Table 1), the most crucial
clinical event associated with poor prognosis of HCC
after hepatectomy [6,19]. As listed in Table 2, multivari-
ate analysis showed that Aurora B overexpression (odds
ratio [OR], 4.679; P = 0.0011], tumor size (OR, 3.735; P
=0 . 0 0 3 1 ) ,t u m o rs t a g e( O R ,3 . 6 1 1 ;P = 0.0073), and age
≤55 years (OR, 1.043; P = 0.0245) were significant inde-
pendent risk factors by Cox’s proportional hazards
model for the occurrence of ETR. A conditional effect
plot of age and Aurora B overexpression on ETR was
drawn based on the multiple logistic regression model
with fixed tumor size and stage (Fig. 2B). The probabil-
ity of ETR was significantly higher in patients with HCC
showing Aurora B overexpression. Furthermore, ETR
(OR, 29.181; P < 0.0001), tumor grade (OR, 1.516; P =
0.0041), and tumor size (OR, 1.072; P = 0.0048) were
significant independent risk factors associated with poor
patient survival (Table 2). Principally, we found that
Aurora B overexpression was an independent risk factor
associated with high-stage tumor (OR, 7.439; P =
0.0003; Table 2) and ETR (OR, 4.679; P = 0.0011),
hence contributing to poor patient survival. Neverthe-
less, Aurora B overexpression did not exert prognostic
effects for tumor size or tumor grade (Table 2).
Interaction of Aurora B overexpression with Aurora A
overexpression and mutations of p53 and b-catenin in
hepatocellular carcinoma
Because both Aurora A and Aurora B correlate closely
with unfavorable prognosis of HCC and may be poten-
tial therapeutic targets [11,12], we analyzed the possible
interplay between these two important biomarkers. In
this study, Aurora A overexpression, which was found in
100 (63%) of 160 HCCs examined, significantly corre-
lated with Aurora B overexpression (P = 0.0003; Table
1). Moreover, as shown in Table 3, HCC with overex-
pression of both Aurora A and Aurora B showed the
highest occurrence of high serum AFP level (≥200 ng/
mL; 71%), large tumor size (> 5 cm; 72%), grade II to IV
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tion (64%), wild-type b-catenin (92%), and the worst 5-
year survival rate (19%) than the other groups.
Because Aurora B overexpression was correlated with
Aurora A overexpression (P = 0.0003), p53 mutation (P
= 0.002), and infrequent b-catenin mutation (P =0 . 0 0 2 )
in this study (Table 1), we then analyzed the prognostic
value of Aurora B overexpression for patient survival in
relation to Aurora A overexpression and p53/b-catenin
mutations. We showed that HCC with Aurora B overex-
pression was associated with worse 5-year survival
regardless of Aurora A expression status (P =0 . 0 1 3f o r
HCC without Aurora A overexpression and P =0 . 0 0 1
for HCC with Aurora A overexpression; Fig. 3A), p53
mutation (P = 0.016 in wild-type p53 HCC and P =
0.123 in p53-mutated HCC; Fig. 3B), and b-catenin
mutation (P = 0.329 in b-catenin-mutated HCC and P <
0.001 in wild-type b-catenin HCC; Fig. 3C).
Anticancer effects of Aurora B kinase selective inhibitor,
AZD1152-HQPA, in HCC cells
The association of Aurora B overexpression and tumor
invasiveness of HCC prompted us to explore the effects
of Aurora B kinase inhibition on HCC cell viability.
Huh-7 and Hep3B cells were treated with increasing
concentrations of an Aurora B selective small-molecule
inhibitor, AZD1152-HQPA, for 72 hours. Concentra-
tion-dependent inhibitory effects of cell viability were
observed in both cell lines (Fig. 4A). The ratios of viable
Huh-7 and Hep3B cells consistently decreased with
higher concentrations of AZD1152-HQPA. The 50%
inhibitory concentrations of cell viability (IC50)a t7 2 - h r
were 16.72 ± 2.44 nM and 4.79 ± 1.03 nM for Huh-7
and Hep3B, respectively (Fig. 4A). Aurora A autopho-
sphorylation at T288 [29] and histone H3 phosphoryla-
tion at Ser10 [12] represent the activity of Aurora A and
Aurora B, respectively. As shown in Fig. 4B, AZD1152-
Figure 1 Overexpression of Aurora B in hepatocellular carcinoma. (A) Aurora B mRNA expression in paired hepatocellular carcinoma (H) and
nontumorous liver parenchyma (L) was measured by quantitative RT-PCR in the exponential phase of amplification. Overexpression of Aurora B
(Aurora B/S26 ratio > 0.5) was detected in 9 of 13 representative tumor samples and in 2 nontumorous liver tissues. Tumor stage and tumor size
are depicted above. (B) Protein lysates and mRNA from nontumorous liver tissues and 7 liver cancer cell lines were analyzed by immunoblotting
and quantitative RT-PCR. All 7 liver cancer cell lines show overexpression of Aurora B at protein level (top panel). The mRNA expressions were
correlated with protein levels (bottom panel).
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primary unifocal HCC by univariate logistic regression analyses
Feature Aurora B overexpression
Total n (%) OR (95% CI)* P value
Age
> 55 88 49 (56) 1.0
≤55 72 49 (68) 1.7 (0.89-3.25) 0.11
Gender
Female 38 23 (61) 1.0
Male 122 75 (61) 1.04 (0.49-2.19) 0.916
HBsAg
Negative 53 27 (51) 1.0
Positive 107 71 (66) 1.9 (0.97-3.72) 0.06
Anti-HCV
Negative 100 68 (68) 1.0
Positive 53 30 (57) 0.8 (0.41-1.57) 0.517
AFP
< 200 80 33 (41) 1.0
≥200 80 65 (81) 6.17 (3.01-12.63) < 0.0001
Child-Pugh
A 147 93 (63) 1.0
B 11 5 (45) 0.48 (0.14-1.66) 0.24
Cirrhosis
No 99 66 (67) 1.0
Yes 61 32 (52) 0.55 (0.29-1.06) 0.073
Size (cm)
≤5 72 37 (51) 1.0
> 5 88 61 (69) 2.14 (1.12-4.08) 0.021
Grade
I 31 10 (32) 1.0
II 74 48 (65) 3.88 (1.59-9.46)
III-IV 55 40 (73) 5.6 (2.15-14.61) 0.0007
Stage
I-II 66 21 (32) 1.0
IIIA-IV 94 77 (82) 9.71 (4.64-20.3) < 0.0001
ETR†
No 76 28 (37) 1.0
Yes 73 61 (84) 8.71 (4.02-18.91) < 0.0001
5-year survival
Yes 56 22 (39) 1.0
No 104 76 (73) 4.19 (2.11-8.36) < 0.0001
Aurora A overexpression
No 60 26 (43) 1.0
Yes 100 72 (72) 3.36 (1.72-6.58) 0.0003
p53 mutation
No 68 34 (50) 1.0
Yes 66 50 (76) 3.13 (1.5-6.53) 0.002
b-catenin mutation
No 128 85 (66) 1.0
Yes 22 7 (32) 0.24 (0.09-0.62) 0.002
*OR: odds ratio; CI: confidence interval
†ETR: early tumor recurrence within 12 months after surgery
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Page 6 of 14Figure 2 Aurora B overexpression predicts early tumor recurrence and poor prognosis. (A) Cumulative survival curve for 160 patients with
primary unifocal hepatocellular carcinoma (HCC). HCC with Aurora B mRNA overexpression, designated Aurora B (+), had significantly worse 5-
year survival than HCC without Aurora B mRNA overexpression, designated Aurora B (-). (B) Conditional effect plot of age on ETR with or without
overexpression of Aurora B mRNA. Based on multiple logistic regression model (n = 149). The other independent variables were fixed as size
> 5 cm and stage III-IV.
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in a concentration-dependent manner, while the phos-
phorylation level of Aurora A (T288) did not change.
The data suggest that AZD1152-HQPA exerts its antic-
ancer effects in HCC cells through the inhibition of
Aurora B.
Because Aurora kinase inhibitors have been shown to
induce cell death after the cell cycle has been disturbed
[10]. We therefore investigated the effects of AZD1152-
HQPA on HCC cell cycle progression and apoptosis. As
shown in Fig. 5A, AZD1152-HQPA treatment resulted
in accumulation of Hep3B cells with 4N DNA contents
at 24-h, followed by the appearance of cells with 8N
DNA contents at 48-h. Our data demonstrated that
AZD1152-HQPA induced cell cycle disturbance in a
concentration-dependent manner (Fig. 5A). We also
examined the ability of AZD1152-HQPA to induce
apoptosis in HCC cells. As shown in Fig. 5B, AZD
1152-HQPA induced concentration-dependent apoptosis
in both Huh-7 and Hep3B cells. After 48 hours of treat-
ment with AZD1152-HQPA above 25 nM, the sub-G1
fractions of Huh-7 cells and Hep3B cells significantly
increased (P < 0.01). In Fig. 5B, AZD1152-HQPA
induced apoptosis more efficiently in Hep3B cells, which
is in accordance with the antiproliferative effects.
Discussion
In mammals, there are three highly related Aurora
kinases: Aurora A, B, and C. These 3 closely related
k i n a s e ss h a r eah i g hd e g r e eo fs e q u e n c eh o m o l o g yi n
their catalytic domains [30]. Despite the sequence
homology and common association with mitotic regula-
tory events, the subcellular localization and signaling
substrates differ, and hence the functions of Aurora A
a n dA u r o r aBa r ee s s e n t i a l l yd i s t i n c t[ 1 3 ] .W eh a v e
reported that Aurora A is highly expressed in HCC and
that overexpression is closely associated with aggressive
tumor phenotypes and worse patient prognosis [11], but
the clinicopathologic significance of Aurora B in HCC
progression remains to be clarified. In this study, we
demonstrated that overexpression of Aurora A and Aur-
ora B was detected in 63% and 61% of 160 surgically
resected, primary unifocal HCCs, respectively. Impor-
tantly, Aurora B mRNA expression correlated with
major clinicopathologic parameters related to tumor
progression by univariate analyses, including high AFP
level (P < 0.0001), large tumor size (P = 0.021), higher
tumor grade (P = 0.0007), and higher tumor stage (P <
0.0001). By multivariate analyses, we showed that Aur-
ora B overexpression was associated with high-stage
(stages IIIA, IIIB, and IV) HCC, which exhibits vascular
invasion and various extent of microscopic intrahepatic
spread (OR, 7.439; P = 0.0003). These findings suggest
that overexpression of Aurora B is associated with
tumor invasion and intrahepatic metastasis of HCC, as
having been shown in Aurora A [11].
Although the diagnosis and management of HCC have
progressed significantly, the prognosis for patients receiv-
ing surgical treatment remains poor because of the high
ETR [6,31]. Hence, the identification of molecular factors
Table 2 Multivariate analyses of the risk factors
associated with ETR, tumor size, tumor stage, tumor
grade, and survival of the patients with primary unifocal
HCC
Covariate Variable
Estimate
SE Wald c
2 P OR
ETR (yes)
a
Intercept -0.2071 1.1146 0.0345 0.8526 –
Aurora B
↑*
1.543 0.4721 10.6826 0.0011 4.679
Size 1.3177 0.4451 8.7658 0.0031 3.735
Stage 1.2839 0.4789 7.1876 0.0073 3.611
Age ≤55 0.0414 0.0184 5.0581 0.0245 1.043
Size
b
Intercept -0.7535 0.4762 2.5037 0.1136 –
p53
mutation
1.5197 0.4828 9.9073 0.0016 4.571
Aurora A
↑
1.1577 0.4937 5.48 0.0192 3.176
HCV -1.0277 0.4958 4.2961 0.0382 0.358
Cirrhosis -1.1187 0.4989 5.0291 0.0249 0.327
Stage III-IV
c
Intercept -4.3949 1.1039 15.8508 < 0.0001 –
Aurora B
↑
2.0067 0.5516 13.2351 0.0003 7.439
p53
mutation
1.0769 0.5399 3.9782 0.0461 2.936
Grade 1.0442 0.3965 6.9351 0.0085 2.841
Size 0.2495 0.0755 10.9173 0.001 1.283
Grade
d
Intercept 0.4449 0.4037 1.2146 0.2704 –
HBV 0.8776 0.3814 5.2947 0.0214 2.405
p53
mutation
0.8058 0.3677 4.8033 0.0284 2.239
AFP 0.8056 0.3808 4.4754 0.0344 2.238
b-catenin
mutation
-1.4923 0.5578 7.1569 0.0075 0.225
Survival time
ETR 3.3735 0.5685 35.2186 < 0.0001 29.181
Grade 0.4158 0.1448 8.2453 0.0041 1.516
Size 0.0698 0.0247 7.9621 0.0048 1.072
aLogistic regression model: n = 149, percentage of concordant pairs = 86.5%,
percentage of discordant pairs = 13.3%, adjusted generalized R
2 = 0.3755,
Hosmer and Lemeshow goodness-of-fit test P = 0.4583 (degrees of freedom = 8).
bLogistic regression model: n = 120, percentage of concordant pairs = 84.3%,
percentage of discordant pairs = 14.4%, adjusted generalized R
2 = 0.3507,
Hosmer and Lemeshow goodness-of-fit test P = 0.3603 (degrees of freedom = 8).
cLogistic regression model: n = 125, percentage of concordant pairs = 90.9%,
percentage of discordant pairs = 8.9%, adjusted generalized R
2 = 0.4647, Hosmer
and Lemeshow goodness-of-fit test P = 0.7933 (degrees of freedom = 8).
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Page 8 of 14to predict ETR will help develop better strategies for
patient management. Here, we showed that HCC with
Aurora B overexpression had a greater than 2-fold higher
chance of ETR than HCC without the overexpression
(OR, 8.71; 95% confidence interval [CI], 4.02-18.91; P <
0.0001). Consistent with its association with high-stage
HCC and frequent ETR, HCC with Aurora B overexpres-
sion showed worse 5-year survival than those without the
overexpression (OR, 4.19; 95% CI, 2.11-8.36; P < 0.0001).
The multivariate analysis confirmed that Aurora B overex-
pression was an independent risk factor associated with
ETR (OR, 4.679; P = 0.0011; Table 2). These findings are
consistent with the correlation of Aurora B overexpression
with poor tumor differentiation and worse patient survival
in thyroid [32], prostate [33], and hepatobiliary cancers
[34,35]. Taken together, our findings suggest that Aurora
B overexpression serves as a useful marker predicting ETR
and hence poor prognosis.
In the present study, we showed that the expression
of Aurora B and Aurora A were closely correlated
(P = 0.0003; Table 1) and exhibited an interaction con-
tributing to HCC progression. HCC with overexpression
of both kinases exhibited the highest rates of high AFP
level (71%), vascular invasion (stage IIIA-IV; 82%), and
ETR (74%), 4-fold higher than those without overexpres-
sion of either kinase (15%, 15%, and 12%, respectively).
Consistently, HCC with overexpression of both kinases
showed the lowest 5-year survival (19%), approximately
one-third of those without any overexpression (56%).
Our findings suggest that Aurora A and Aurora B con-
tribute cooperatively to a more malignant HCC pheno-
type, ETR, and poor prognosis.
HCC has been classified into two major groups
according to chromosomal stability status [36]; tumors
characterized by chromosomal instability were asso-
ciated with more p53 mutation and less b-catenin
mutation, the two major genetic mutations in human
HCC [17,24,25]. Mutation of p53 correlated with
aggressive HCC and poor prognosis [24,25], whereas
b-catenin mutation was associated with less tumor
aggression and more favorable prognosis [17]. We also
showed that Aurora A overexpression correlated posi-
tively with p53 mutation and inversely with b-catenin
mutation [11]. In the present study, we showed that
Table 3 Cooperations of Aurora B and Aurora A mRNA expressions in relation to clinicopathologic and molecular
features in 160 patients with primary unifocal HCC
Feature Aurora B / Aurora A expression number (%) P value
+/+ (n = 72) +/- (n = 26) -/+ (n = 28) -/- (n = 34)
AFP < 0.0001
< 200 21 (29) 12 (46) 18 (64) 29 (85)
≥200 51 (71) 14 (54) 10 (36) 5 (15)
Size (cm) < 0.0001
≤5 20 (28) 17 (65) 11 (39) 24 (71)
> 5 52 (72) 9 (35) 17 (61) 10 (29)
Grade 0.0014
I 4 (6) 6 (23) 8 (29) 13 (38)
II 36 (50) 12 (46) 10 (36) 16 (47)
III-IV 32 (44) 8 (31) 10 (36) 5 (15)
Stage < 0.0001
I-II 13 (18) 8 (31) 16 (57) 29 (85)
IIIA-IV 59 (82) 18 (69) 12 (43) 5 (15)
p53 mutation 0.0099
No 22 (36) 12 (52) 15 (65) 19 (70)
Yes 39 (64) 11 (48) 8 (35) 8 (30)
b-catenin mutation 0.0024
No 61 (92) 24 (92) 23 (85) 20 (65)
Yes 5 (8) 2 (8) 4 (15) 11 (35)
ETR < 0.0001
No 17 (26) 11 (46) 19 (70) 29 (88)
Yes 48 (74) 13 (54) 8 (30) 4 (12)
5-year survival 0.0003
Yes 14 (19) 8 (31) 15 (54) 19 (56)
No 58 (81) 18 (69) 13 (46) 15 (44)
Abbreviation: +, present; -, absent
Lin et al. BMC Cancer 2010, 10:461
http://www.biomedcentral.com/1471-2407/10/461
Page 9 of 14Aurora B overexpression positively correlated with p53
mutation (P = 0.002) and inversely with b-catenin
mutation (P = 0.002). Despite the association with
these important molecular factors, Aurora B overex-
pression predicted worse 5-year survival regardless of
Aurora A expression status, p53 mutation, or b-catenin
mutation (Fig. 3). Hence, it is suggested that Aurora B
overexpression, independent of Aurora A overexpres-
sion and p53/b-catenin mutations, is an important
molecular factor associated with vascular invasion,
leading to high-stage tumor, ETR, and poor prognosis
for patients with surgically resected HCC.
Since the discovery of Aurora kinases, Aurora A has
attracted much attention as an appealing therapeutic
Figure 3 Cumulative survival curve for HCC in relation to increased or normal expression of Aurora B and the presence or absence of
Aurora A overexpression (A), p53 mutation (B), and b-catenin mutation (C).
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Page 10 of 14Figure 4 Aurora B kinase selective inhibitor, AZD1152-HQPA, shows antiproliferative effects in HCC cells. (A) Concentration-dependent
inhibitory effects of AZD1152-HQPA on cell viability in Huh-7 and Hep3B cell lines. Cells were treated with AZD1152-HQPA at 1, 5, 25, and 125
nM in 10% FBS-supplemented medium for 72 hours; cell viability was determined by trypan blue assay. Columns: means; bars:S D( n = 3). §, p <
0.05; *, p < 0.01 (compared with untreated controls). The changes in cell counts and morphologic features are shown in the lower panels
(magnification, × 100). (B) Huh-7 and Hep3B cells were treated with AZD1152-HQPA for 24 hours. The cell lysates were then immunoblotted.
Histone H3 (Ser10) phosphorylation, the key substrate of Aurora B signaling, was downregulated in a concentration-dependent manner. Aurora A
(T288) phosphorylation, the key substrate of Aurora A signaling, was not repressed by AZD1152-HQPA treatments.
Lin et al. BMC Cancer 2010, 10:461
http://www.biomedcentral.com/1471-2407/10/461
Page 11 of 14target because of its oncogenic potential [37], and the
frequent overexpression of Aurora A in a variety of
human cancers [38]. However, subsequent pharmacolo-
gic studies demonstrated that dual Aurora A and Aur-
ora B kinase inhibitors produced biologic responses
equivalent to Aurora B disruption alone [10], suggesting
that Aurora B is a critical therapeutic target for cancer.
We previously reported that a novel dual Aurora A and
Aurora B kinase inhibitor, VE-465, had anticancer
effects in human HCC [12]. Hence, determining whether
Aurora A or Aurora B is the pertinent therapeutic target
for HCC is imperative. In the present study, we first
showed that Aurora B overexpression was associated
with major clinical (high AFP, ETR) and histopathologic
(large tumor, higher tumor grade, and higher tumor
stage) features, which are critical for tumor progression
of HCC, and hence is an independent risk factor for
poor prognosis of patients with surgically resected HCC.
In addition, we showed AZD1152-HQPA, an Aurora B
selective inhibitor, has anticancer effects in HCC cells.
AZD1152-HQPA treatment resulted in profound inhibi-
tion of Aurora B signaling, which in turn led to cell
cycle disturbance, apoptosis, and growth suppression in
HCC cells. Our results suggest that Aurora B selective
inhibitors are potential drugs for HCC treatment, con-
firming the observation that AZD1152 is a novel pro-
mising therapeutic approach for HCC [39].
Nevertheless, whether targeting Aurora B kinase alone is
a better therapeutic strategy, compared with the target-
ing of both Aurora A and Aurora B kinases, will require
further exploration.
Conclusion
In this study, we showed frequent overexpression of
Aurora B in HCC, which was closely associated with
aggressive tumor phenotypes. Aurora B overexpression,
independent of Aurora A overexpression and p53/b-
catenin mutations, is an important molecular marker
associated with early recurrence and poor prognosis.
Besides, an Aurora B kinase selective inhibitor,
AZD1152-HQPA, had anticancer effects in HCC cells.
These findings indicate the importance of Aurora B
kinase in HCC progression and as a potential therapeu-
tic target for HCC.
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